Part 2 of our interview with Todd Harrison, co-chair of the FDA practice group at Venable LLP covers preclusion's structural gaps: no defined end point, no tracking registry, and a push for mandatory drug-sponsor engagement.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, details the Dietary Supplement Innovation Act's language, its unintended consequences, and what industry stakeholders should watch for.

Piping Rock Health Products has launched a 300-mg NMN gummy under its Vitafusion brand, arriving less than a year after the FDA reversed its position on whether the ingredient could legally be sold as a dietary supplement.

The Dietary Supplement Innovation Act, introduced by Rep. Harshbarger, would cap indefinite preclusion, require science-based review standards, and open FDA warnings to court challenge.

At the Future Nutra Innovation Summit, Sibyl Swift, PhD, founder and principal of Swift Strategy Group, discusses supplement oversight and unpacks why mandatory product listing divides the industry.

The inaugural Future Nutra Innovation Summit opened with organizers pitching a networking-first alternative to the traditional trade show, followed by an NSF presentation on certification failure rates and consumer trust that set a tone for the rest of the event.

This overview outlines the clinical background, consumer landscape, and technical developments shaping the gluten-free category.

The company's newest chewable concepts pair postbiotics with biotin and vitamin D3 to support skin, hair, and immune health.